Innovating Works

FUNDACION PRIVADA DE LUCHA CONTRA EL SIDA

Activa
RBDCOV: RBD Dimer recombinant protein vaccine against SARSCoV2 HIPRA SCIENTIFIC tramitó un HORIZON EUROPE: The main objective of RBDCOV project is to test the efficacy, tolerability, and safety of a new vaccine against different variants of COVID-19 based on the outstanding data generated using a recombina...
2021-11-12 | Financiado
Trep-AB: Repurposing clinically approved antibacterial drugs for treponematoses therapy FUNDACION PRIVADA DE LUCHA CONTRA EL SIDA tramitó un FP7: Current therapeutic options for human treponematoses, syphilis and yaws, are, broadly speaking, restricted to one antibiotic: injectable penicillin. The drug susceptibility profile of Treponema pallid...
2020-02-01 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.